MedTrace Logo

Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).

NCT00331253 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2007-04-27

No results posted yet for this study

Summary

To establish the safety and efficacy of indocyanine green-mediated photothrombosis (i-MP) for the treatment of patients with neovascular age-related macular degeneration.

Conditions

  • Maculopathy, Age-Related

Interventions

PROCEDURE

Indocyanine Green-Mediated Photothrombosis

Sponsors & Collaborators

  • Opto Eletronica S.A.

    lead INDUSTRY

Principal Investigators

  • Elizeu Ramos, M.S. · Opto Eletrônica S.A.

  • Avila Marcos, MD · Universidade Federal de Goias

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Completion
2008-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331253 on ClinicalTrials.gov